Givat Shmuel, Israel – April 7, 2009 – Cimatron Limited (Nasdaq: CIMT), a leading provider of integrated CAD/CAM solutions for mold, tool and die makers as well as manufacturers of discrete parts, announced that CimatronE will be showcased at MEDTEC trade show in Japan on April 7-8th 2009.
In the booth of Saeilo Japan, CimatronE's Japan distributor, a dental part will be scanned into CimatronE using a Roland Laser Scanner LPX-DS Series. CimatronE will automatically generate the toolpath and a part will then be milled using the Roland MDX-40 3D milling machine.
CimatronE users worldwide use the software to shorten delivery time of high precision medical and dental parts. CimatronE is a proven technology covering the entire process of creating a wide range of prosthetics and orthotics including knee and hip joints, plastic medical equipment, dental implants and more.
In addition, CimatronE users cut a wide range of materials confidently including Titanium, aluminum alloys and a wide range of materials used in dental implants, crowns and bridges.
CimatronE is a fully integrated CAD/CAM suite allowing users to handle the entire process from reading scanned data and adapting it for manufacturing to NC programming - all in the same environment.
"Under the current economic conditions, many manufacturing companies are expanding their operations to target the medical industry," said Mr. Kobi Rosenwasser, Cimatron's Vice President Asia Pacific. "CimatronE has proven experience in the global medical industry. We have been pioneers in 3-5 Axis Micro Milling and have an extensive experience in High Speed Milling and cutting of special materials."
Version 9.0 of CimatronE will be on display at MEDTEC and will be available to customers later this year.
With over 25 years of experience and more than 40,000 installations worldwide, Cimatron is a leading provider of integrated, CAD/CAM solutions for mold, tool and die makers as well as manufacturers of discrete parts. Cimatron is committed to providing comprehensive, cost-effective solutions that streamline manufacturing cycles, enable collaboration with outside vendors, and ultimately shorten product delivery time.
The Cimatron product line includes the CimatronE and GibbsCAM brands with solutions for mold design, die design, electrodes design, 2.5 to 5 axes milling, wire EDM, turn, Mill-turn, rotary milling, multi-task machining, and tombstone machining. Cimatron's subsidiaries and extensive distribution network serve and support customers in the automotive, aerospace, medical, consumer plastics, electronics, and other industries in over 40 countries worldwide.
Cimatron is publicly traded on the NASDAQ exchange under the symbol CIMT. For more information, please visit the company web site at: http://www.cimatron.com
This press release includes forward looking statements, within the meaning of the Private Securities Litigation Reform Act Of 1995, which are subject to risk and uncertainties that could cause actual results to differ materially from those anticipated. Such statements may relate to the company's plans, objectives and expected financial and operating results. The words "may," "could," "would," "will," "believe," "anticipate," "estimate," "expect," "intend," "plan," and similar expressions or variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of the future performance and involve risks and uncertainties, many of which are beyond the company's ability to control. The risks and uncertainties that may affect forward looking statements include, but are not limited to: currency fluctuations, global economic and political conditions, marketing demand for Cimatron products and services, long sales cycle, new product development, assimilating future acquisitions, maintaining relationships with customers and partners, and increased competition. For more details about the risks and uncertainties of the business, refer to the Company's filings with the Securities and Exchanges Commission. The company cannot assess the impact of or the extent to which any single factor or risk, or combination of them, may cause. Cimatron undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.